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Abstract
Background: Metastasis is the most pivotal cause of mortality in cancer patients. Immune tolerance plays a crucial role in
tumor progression and metastasis.
Methods and Findings: In this study, we investigated the potential roles and mechanisms of TLR2 signaling on tumor
metastasis in a mouse model of intravenously injected B16 melanoma cells. Multiple subtypes of TLRs were expressed on
B16 cells and several human cancer cell lines; TLR2 mediated the invasive activity of these cells. High metastatic B16 cells
released more heat shock protein 60 than poor metastatic B16-F1 cells. Importantly, heat shock protein 60 released by
tumor cells caused a persistent activation of TLR2 and was critical in the constitutive activation of transcription factor
Stat3, leading to the release of immunosuppressive cytokines and chemokines. Moreover, targeting TLR2 markedly
reduced pulmonary metastases and increased the survival of B16-bearing mice by reversing B16 cells induced
immunosuppressive microenvironment and restoring tumor-killing cells such as CD8
+ T cells and M1 macrophages.
Combining an anti-TLR2 antibody and a cytotoxic agent, gemcitabine, provided a further improvement in the survival of
tumor-bearing mice.
Conclusions and Significance: Our results demonstrate that TLR2 is an attractive target against metastasis and that
targeting immunosuppressive microenvironment using anti-TLR2 antibody is a novel therapeutic strategy for combating a
life-threatening metastasis.
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Introduction
Tumor metastases are the most common cause of death in cancer
patients but there are no effective therapies to target the
development and progression of metastases [1]. Recent evidence
highlights that tumor metastasis requires collaborative interactions
between tumor cells and immune cells at both primary and
secondarytumorlocations[2].Actually,immune responsefunctions
as a double-edged sword: it is recognized as the surveillance
component for the host to eliminate tumor cells and attenuate the
development of metastases on one hand; it is also accepted as the
mediator promoting primary tumor metastasis on the other hand
[3]. A large number of infiltrating immune cells, such as regulatory
T cells (Tregs), tumor-related macrophages, and mast cells,
contribute to cancer growth, angiogenesis, metastasis, and tumor
immune tolerance [4]. Indeed, an accumulation of suppressive
factors and a reduction of tumoricidal factors in the tumor
microenvironment are responsible for the fail of tumor immuno-
surveillance, leading to tumor progression and metastasis [5].
Although the mechanism is still to be elucidated, transcription
factor Stat3 is constitutively activated at a very high level in cancer
cell lines and tumors [6]. The constitutively-activated Stat3
(cStat3) mediates a crosstalk between tumor cells and host immune
cells to direct immunosuppressive response in tumor tissues.
Blocking Stat3 in highly metastatic melanoma cells suppresses the
invasion of the cells and lung metastases; enforcing the expression
of cStat3 converts poorly metastatic melanoma cells into highly
metastatic cells [7]. Thus, Stat3 provides a link between
oncogenesis and immunosuppression and plays a central role in
the establishment of immunosuppressive environment and the
progression of tumors [8].
TLRs have recently emerged as critical components of the
immune system to sense danger signals, initiate innate immune
response, and direct the polarization of adaptive immune
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pathogens by recognizing highly conserved pathogen-associated
molecular patterns (PAMPs) in the pathogens. Also, TLRs induce
chronic inflammation or immune tolerance after being activated
by damage-associated molecular patterns (DAMPs) such as
HMGB1, HSPs, and S100 proteins released from injured tissue
or tumor tissue [10,11]. In general, stimulation of TLR3, 4, 7, 8,
or 9 induces a TH1 or TH17 type of immune response; whereas
stimulation of TLR2 induces a TH2, Treg, or TH17 type of
immune response [12,13]. Obviously, TLR2 has an unique
position in the regulation of tumor tolerance, cancer progression
and metastasis [3]. Indeed, we recently find that targeting TLR2
reverses pulmonary fibrosis through regulating immunosuppres-
sive microenvironment [14]. We therefore wonder if TLR2
signaling has a role in the regulation of tumor metastasis. We
found that the basal activity of TLR2 determines the evasive
capacity and the level of immunosuppressive factors in tumor cells.
Targeting TLR2 significantly attenuated pulmonary metastases of
B16 melanoma and animal death. Our study provides strong
evidence to directly demonstrate that targeting TLR2 to overcome
tumor cell-induced immunosuppressive microenvironment is a
novel therapeutic strategy against tumor metastasis.
Results
TLR2 mediated the invasion capacity and the production
of immunosuppressive factors in B16-F10 melanoma cells
To determine the potential roles of TLRs in the regulation of
the tumor cell-induced immune tolerance, we first examined if
tumor cells expressed TLRs. We found that TLR2 and TLR4
were expressed on B16 cells (Figure S1A and B). The expressions
of TLR2 and TLR4 on B16 cells were significantly inhibited by a
corresponding TLR2- or TLR4- shRNA (Figure S1A) and up-
regulated by LPS treatment (Figure S1B). B16 cells also expressed
other members of the TLR family including TLR1, TLR3, TLR5,
TLR6 and TLR7 (Figure S1C). We further examined the roles of
TLR2 and TLR4 on cell migration and growth of B16 cells. TLR2
knockdown (KD), but not TLR4 KD, significantly inhibited the
invasive activity of B16 cells by about 35% compared with the
vector control (P,0.001, Fig. 1A and B). Additionally, agonist of
either TLR2 or TLR4 promoted the growth of B16 cells (P,0.05,
Figure S1D). However, TLR2 or TLR4 KD did not affect the
growth of B16 cells (P.0.05, Figure S1D). Since TLR2 functions
via dimerization with TLR1, TLR6, or Dectin-1, respectively [15],
we examined the dimerizing partners of TLR2 in these cells and
found that TLR2 co-localized with TLR6 or Dectin-1, but not
TLR1 (Fig. 1C). Thus, treatment of B16 cells with shRNA against
either TLR2 or TLR6 attenuated the invasive activity of B16 cells,
and treatment of these cells with TLR2-shRNA plus TLR6-
shRNA further inhibited the invasive activity of B16 cells
compared to TLR2-shRNA or TLR6-shRNA treatment alone
(P,0.001, Fig. 1D). Also, Dectin-1 shRNA significantly inhibited
the invasion of B16 cells, and Dectin-1-shRNA plus TLR2-shRNA
synergized the inhibitory effects on the invasive ability of B16 cells
(Fig. 1D). Importantly, TLR2 was expressed on several human
tumor cell lines (Methods S1). Activation of TLR2 by LPS
significantly enhanced the expression of TLR2 on these cells
(Figure S1E). Knockdown of TLR2 markedly reduced the invasive
capability of the high-metastatic cancer cell lines, including A549,
H7402, HCT8 and MDA-MB231, but did not affect the invasive
activity of the low-metastatic cell MCF7 (Fig. 1E). Additionally,
TLR2 agonist Pam3Cys significantly enhanced the production of
several suppressive cytokines, including IL-6, IL-10, IL-13 and
TGF-b1, as well as chemokines MCP-1, CCL22 and their
receptor CCR8 (Fig. S2, Method S2). TLR2 activity mediated
HSP60-stimulated release of the suppressive cytokines, chemo-
kines, and the expression of CCR8 in B16 cells (Fig. S3).
Persistent activation of TLR2 responsible for the cStat3
As illustrated in the Fig. 2, activation of TLR2 resulted in a
significant increase in the expression and phosphorylation of Stat3
in concentration- and time- dependent manner (Fig. 2A–D). In
contrast, activation of TLR4 inhibited the expression and
phosphorylation of Stat3 (Fig. 2A–D). TLR2 KD not only
markedly blocked the Pam3Cys-stimulated expression and phos-
phorylation of Stat3, but also significantly reduced the constitutive
expression and phosphorylation of Stat3 compared to the basal
level of Stat3 in B16 cells (P,0.001, Fig. 2C), suggesting the basal
activity of TLR2 is critical for the constitutive activation of Stat3 in
the tumor cells. However, TLR4 KD enhanced the phosphory-
lation and inhibited the expression of Stat3 (Fig. 2C).
The onset and maintenance of constitutive activity of Stat3 are
associated with the autocrineactivity of IL-6and IL-10 in the tumor
cell [8].We studied if TLR2-inducedStat3 activity depended on the
activation of IL-6/IL-10 pathways. Similar to IL-6 and IL-10,
Pam3Cys significantly promoted the expression, phosphorylation,
and nucleus translocation of Stat3 in B16 cells (Fig. 2D–F). Similar
to the IL-6- plus IL-10- neutralizing Ab, the TLR2 shRNA
markedly inhibited the expression, phosphorylation and nucleus
translocation of Stat3, which were partially restored by rmIL-6 and
rmIL-10 (Fig. 2D–F). In turn, the anti-IL-6 plus IL-10 Abs partially
inhibited the Pam3Cys-stimulated expression, phosphorylation and
nucleus translocation of Stat3 (Fig. 2D–F). These results indicated
that Stat3 mediated the immunosuppressive activity of TLR2 in
B16 cells partially dependent of IL-6/IL-10.
We further investigated the role of Stat3 in the pro-metastatic
effects of TLR2 activation. The activation of TLR2 by Pam3Cys
significantly enhanced the expression of various pro-metastatic
proteins, such as survivin, VEGF and HIF-a (Fig. S4A–C), and
inhibited the expression of the anti-metastatic protein p53
(P,0.01, Fig. S4D). Also, Pam3Cys promoted the expressions of
IL-10, IL-13 and HSP60 (Fig. S4F–H) in B16 cells. In contrast,
knockdown of TLR2 significantly reversed the effects of Pam3Cys
on the expressions of the pro-metastatic proteins, suppressive
cytokines and p53 protein (Fig. S4). Neither Pam3Cys nor the
TLR2 shRNA affected the expression of c-Myc in B16 cells (Fig.
S4E). Inhibition of Stat3 with a specific Stat3 inhibitory peptide
significantly reversed the effects that resulted from the Pam3Cys
stimulation in B16 cells (Fig. S4). Transfection of cells with Stat3C
(S3C, Method S3) maintains Stat3 at a highly activated status [16];
TLR2 knockdown did not change the expression of proteins in
S3C-transfected B16 cells (Fig. S4).
Since the TLR2 basal activity determined the constitutive
activation of Stat3 in tumor cells, we hypothesized that DAMPs
produced by tumor cells resulted in a persistent activation of
TLR2 in the tumor cells. We found that the high-metastatic B16
cells released much more HSP60 than the low-metastatic B16-F1
cells cultured without or with lower serum concentrations (Fig.
S5A). The alveolar epithelial cells did not release HSP60 under the
same conditions as the B16 cells did (data not shown). Knockdown
of TLR2 significantly attenuated the HSP60-stimulated expres-
sions of VEGF (P,0.01), IL-10 (P,0.01), and the phosphorylation
of Stat3 (P,0.01) (Fig. S5B–D).
Blocking TLR2 attenuated the pulmonary metastases of
B16 cells and animal death
Based on these in vitro findings, we examined if TLR2 KD
(TLR2KD-B16) or TLR4 KD (TLR4KD-B16) in B16 cells
TLR2 and Tumor Metastasis
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TLR2KD-B16 markedly decreased the pulmonary metastatic
nodes by 5 fold (P,0.001, Fig. 3C), and subsequently greatly
reduced animal death (P,0.001, Fig. 3A). However, TLR4KD-
B16 aggravated the pulmonary metastasis and animal death
(Fig. 3A, C–D). Also, we examined if targeting TLR2 or TLR4 by
intravenous injection of a TLR2- or TLR4-neutralizing Ab
prophylactically (TLR2pre or TLR4pre) or therapeutically
(TLR2aft) attenuated pulmonary metastasis of B16 cells in
C57BL/6J mice. The neutralizing anti-TLR2 or anti-TLR4 Ab
had been proved to block TLR2- or TLR4-mediated responses,
respectively [14,17,18]. Injection of B16 cells resulted in a
significant pulmonary metastasis and animal death (Fig. 3A–D).
Both the TLR2pre and TLR2aft markedly increased the
accumulating survival rate over 50% (Fig. 3A) and attenuated
pulmonary metastasis (Fig. 3C). Combining the TLR2 Ab and
Figure 1. TLR2 was responsible for the invasion of tumor cells. (A–B) Knockdown of TLR2 attenuated the invasion of B16 cells. B16 cells were
seeded in transwell plates (5000 cells per well) and treated with Ec-LPS (100 ng/mL), Pam3Cys (1 mg/mL), TLR2- or TLR4-shRNA or bleomycin (10 mU/
mL) for 48 h. (C) TLR2 co-localized with TLR6 or Dectin-1 on B16 cells. Data is a representative of three independent experiments. Original
magnification is 5006. (D) Knockdown of TLR2/TLR6 or TLR2/Dectin-1 resulted in a synergized inhibition of B16 cell invasion. Data is representative of
two independent experiments in duplicates. Original magnification is 2006. (E) TLR2 mediated the invasive activity of multiple human tumor cell
lines. The data is a representative image of two independent experiments. Original magnification is 2006.
doi:10.1371/journal.pone.0006520.g001
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6520Figure 2. TLR2 KD inhibited the constitutive activity of Stat3 dependent of the IL-6/IL-10 signal pathway. The B16 cells were as
indicated for 24 h. Cells were stained with pStat3 FITC or Stat3 TRITC Ab and the expression or phosphorylation of Stat3 was analyzed by intracellular
flow cytometry. (A, B) Activation of TLR2 resulted in a concentration- and time-dependent phosphorylation (A) and expression (B) of Stat3 in B16 cells.
(C) TLR2 KD, but not TLR4 KD, inhibited the expression and phosphorylation of Stat3 in B16 cells. (D, E) Activation of TLR2 enhanced the expression
(D) and phosphorylation (E) of Stat3 in an IL-6 or IL-10-independent way. The cells in a medium containing 5% serum were treated as indicated in the
methods section. The phosphorylation of Stat3 was analyzed by intracellular flow cytometry. Data are represented as mean6SE of four independent
experiments. F, TLR2 activation resulted in a nucleus translocation of Stat3 dependent of IL-6 or IL-10. B16 cells were treated as indicated, and the
nucleus translocation of Stat3 in B16 cells was determined by a confocal laser 3000 Analyzer. Representative micrographs from three translocation
assays were shown (Original magnification, 206). *P,0.05, **P,0.01, ***P,0.001 versus untreated group;
#P,0.05,
##P,0.01,
###P,0.001 versus
Pam3Cys treated group;
ˆP,0.05,ˆ ˆP,0.01,ˆ ˆ ˆP,0.001 versus TLR2 ShRNA treated group.
doi:10.1371/journal.pone.0006520.g002
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6520Figure 3. Targeting TLR2 attenuated pulmonary metastases of B16 cells. The mice were treated as described in the methods. (A, B) The
survival rate of mice injected with B16 cells. The animal survival rate was analyzed by the Kaplan-Meier method (n§30). (C) Targeting TLR2, but not
TLR4, reduced the pulmonary metastasis nodes. Left, representative lung photographs. The animals were treated as a) sham; b) B16 cells; c) IgG; d)
TLR2aft; e) TLR2pre; f) TLR4pre; g) TLR2KD-B16; and h) TLR4KD-B16. Right, summary of the pulmonary metastasis nodes. (D) The representative H&E
staining image of the lungs. The nuclear division stage was assessed by H&E staining that represented a nuclear division scale. (E) The level of HSP60
in BALF detected with ELISA. (F) The phosphorylation of Stat3 in the lung of B16 melanoma-bearing mice. Data are represented as mean6SE of three
independent experiments (n=15/group/experiment). *P,0.05, **P,0.01, ***P,0.001 versus B16 cell bearing mice;
#P,0.05,
##P,0.01,
###P,0.001 versus normal mice.
doi:10.1371/journal.pone.0006520.g003
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tic efficacy of treating the pulmonary metastasis of B16 cells and
the survival rate of tumor-bearing mice compared to mice treated
with GC alone (P,0.001, Fig. 3B). Targeting TLR2, including
TLR2pre, TLR2aft or TLR2KD-B16, significantly reduced the
enhanced HSP60 in BALF of B16-bearing mice, but targeting
TLR4 did not (Fig. 3E). To assess the activity of the invasive
melanoma cells, we further analyzed the nuclear division stages in
the lung. The results indicated that TLR2KD-B16, TLR2pre, or
TLR2aft significantly reduced the nuclear division stages of the
invasive B16 cells (Fig. 3D). Moreover, targeting TLR2 in the host
or in the melanoma cells markedly inhibited the B16 cell-induced
phosphorylation of Stat3 (Fig. 3F). In contrast, TLR4 KD in B16
cell enhanced the phosphorylation of Stat3 although systemic
administration of the anti-TLR4 Ab did not (Fig. 3F).
Blocking TLR2 reversed B16 cell-induced inhibitory
immune microenvironment
To investigate the regulatory effects of targeting TLR2 and
TLR4 on the B16 cell-induced immune microenvironment, we
examined the level of cytokines, such as IFN-c, TGF-b1, IL-10
and MCP-1, and the infiltration of immune cells, such as DCs,
macrophages and T cells, in the lungs of the mice. Injection of B16
cells reduced the release of IFN-c and enhanced the production of
TGF-b1, IL-10 and MCP-1 (Fig. 4A–D) in the lungs. TLR2KD-
B16 and TLR2pre markedly reduced the levels of TGF-b1
(Fig. 4B), IL-10 (Fig. 4C), MCP-1 (Fig. 4D) and restored the
release of IFN-c (Fig. 4A). TLR2aft also significantly inhibited the
productions of IL-10 (P,0.001, Fig. 4C) and MCP-1 (P,0.001,
Fig. 4D), but not TGF-b1 (Fig. 4B). However, TLR4pre inhibited
the releases of IL-10 and IFN-c, but enhanced the production of
MCP-1 (Fig. 4). TLR4KD-B16 did not affect the productions of
TGF-b1, IL-10, IFN-c or MCP-1 (Fig. 4). Additionally, injection
of B16 cells resulted in a significant decrease in the number of
infiltrated pro-inflammatory MHCI
+CD11c
+ DCs (P,0.01,
Fig. 5A), MHCII
+ CD11c
+ DCs (P,0.01, Fig. 5B), CD8
+ T cells
(P,0.01, Fig. 5C) and M1 cells (P,0.01, Fig. 5E) and a significant
increase in the number of immune-suppressive FoxP3
+ Tregs
(P,0.001, Fig. 5D) and M2 cells (P,0.05, Fig. 5F). TLR2KD-
B16, TLR2pre, or TLR2aft significantly attenuated the recruit-
ment of FoxP3
+ Tregs and M2 cells (Fig. 5D and F) and promoted
the infiltration of pro-inflammatory immune cells (Fig. 5A–C, E).
However, targeting TLR4 did not alter the recruitment of these
immune cells compared to the B16-bearing mice (Fig. 5).
TLR2 deficiency protected from the pulmonary
metastasis of B16 melanomas
To validate the protection of targeting TLR2 against metastasis
and to exclude possible boosting or inhibitory effects of an anti-
TLR2 Ab by binding to Fc-receptor non-specifically [19], we
investigated if knocking out TLR2/4 affected the metastasis of B16
cells and the tumor cell-induced immunosuppressive microenvi-
ronment. TLR2 deficiency significantly inhibited the metastasis
and progression of melanoma, as well as nucleus division stage
(Fig. 6A–D), leading to a significant reduction in the animal
deaths. TLR2 deficiency markedly increased the infiltration of
tumoricidal CD8
+ T cells (P,0.05, Fig. 6E) and inhibited the
tissue infiltrating FoxP3
+ Tregs (P,0.001, Fig. 6F). Moreover,
injection of TLR2 KD-B16 cells into TLR2 deficient mice resulted
in a further decrease in animal death (P,0.05, Fig. 6A), tumor cell
metastasis and progression (Fig. 6B–E) compared to TLR2
deficient mice injected with the untreated B16 cells. These effects
were associated with the increase of CD8
+ T cells (Fig. 6D). In
contrast, TLR4 deficiency significantly aggravated the metastasis
of B16 melanomas and reduced the survival rate of mice (Fig. 6A–
D). Moreover, TLR4 deficiency significantly enhanced the tissue-
infiltrating Tregs (Fig. 6F), but did not affect the infiltration of
CD8
+ T cells (Fig. 6E).
Figure 4. Targeting TLR2 altered the production of cytokines in the lungs. Animals were treated as indicated in the Figure 3 legend.
Supernatants were obtained from a homogenate of lung tissue to detect the levels of cytokines, including IFN-c (A), TGF-b1 (B), IL-10 (C), and MCP-1
(D). Data are represented as mean6SE of three independent experiments (n=8/group/experiment). *P,0.05, ** P,0.01, ***P,0.001 versus B16 cell
bearing mice;
#P,0.05,
##P,0.01,
###P,0.001 versus sham mice.
doi:10.1371/journal.pone.0006520.g004
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Establishing an active, pathological immune tolerance by tumor
cells is an important mechanism responsible for the tumor
escaping the anti-tumor immunity and for the failure of current
immunotherapeutic strategies against some cancers [20]. Recent
studies indicate that the developing tumors actively interact with
the immune cells to foster an immunosuppressive microenviron-
ment comprised of immunosuppressive cells, cytokines, chemo-
kines, and activated stroma, all of which may promote tumor
survival, growth, angiogenesis, and metastasis [20]. Although the
precise mechanisms governing the tumor-induced immune
tolerance are still elusive, a constitutive activation of Stat3 in
most tumors plays a crucial role in the formation of tumor-induced
immune tolerance [6]. Our studies demonstrate that the activation
TLR2 expressed on B16 cells not only determines the invasiveness
of these cells, but also facilitates tumor metastasis due to promoting
the formation of the immunosuppressive microenvironment.
Moreover, blocking TLR2 signaling retards tumor metastasis
and prolongs the survival of tumor-bearing mice largely associated
to the reversal of the tumor cell-induced immunosuppressive
microenvironment and the restoration of tumor-killing cells, such
as CD8
+ T cells and M1 cells. In contrast to the protective role of
targeting TLR2 in the attenuation of tumor metastasis, targeting
TLR4 aggravates the progress of melanoma metastasis associated
with an enhancement of Stat3 activity and an increase of the
tumor-infiltrating Tregs. These results are consensually supported
by the studies in which TLR4 activation inhibits phosphorylation
and nucleus translocation of Stat3 [21] and activated Stat3 inhibits
TLR4 signaling in return via inhibiting transcriptional or
translational activity of NF-kB [22]. Our results are supported
Figure 5. Targeting TLR2 reversed the tumor cell-induced immunosuppressive microenvironment. Animals were treated as indicated in
the Figure 3 legend. The lungs were removed, and the lung single cell suspensions were prepared as described in the methods section. The various
immune cells, including CD11
+MHC I
+ cells (A), CD11
+MHC II
+ cells (B), CD3
+CD4
+ and CD3
+CD8
+ cells (C), FoxP3
+CD4
+CD25
+ Tregs (D), CD11b
+F4/
80
+CD206
2 M1 cells (E) and CD11b
+F4/80
+CD206
+ M2 cells (F), were detected by flow cytometry. The CD4
+ and CD8
+ cells were gated from CD3
+
cells. The CD4
+CD25
+ Tregs were gated from Foxp3
+ cells. The M1 and M2 were gated from CD11b
+ cells. The data are represented as mean
percentage of positive cells6SE of three independent experiments (n=8/group/experiment). *P,0.05, **P,0.01, ***P,0.001 versus B16-bearing
mice;
#P,0.05,
##P,0.01,
###P,0.001 versus normal mice.
doi:10.1371/journal.pone.0006520.g005
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PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6520Figure 6. TLR2 deficiency markedly protected mice from metastasis and progression of B16 melanoma. (A) TLR2 but not TLR4
deficiency significantly increased the survival of B16 cell bearing mice. The survival rate was analyzed by the Kaplan-Meier method. (B–C) TLR2
deficiency but not TLR4 significantly decreased pulmonary metastasis of B16 cells. Representative lung photographs from the animals treated as
indicated (B), the pulmonary metastatic nodes of B16 cell bearing mice (C). Data are mean6SE of three independent experiments (n=15/group/
experiment). (D) Representative H&E staining images. (E, F) TLR2 but not TLR4 deficiency enhanced the infiltration of CD8
+ T cells (E) and reduced the
infiltration of FoxP3
+ Tregs (F). The lung single cell suspensions were prepared as indicated in the methods section. The CD8
+ T cells and FoxP3
+ Tregs
were detected by flow cytometry. Data are the mean percentage of positive cells6SE of three independent experiments (n=12/group/experiment).
*P,0.05, **P,0.01, ***P,0.001 versus B16 cell bearing WT mice;
#P,0.05,
##P,0.01,
###P,0.001 versus WT mice;
$P,0.05,
$$P,0.01,
$$$P,0.001
versus TLR2 deficient mice.
doi:10.1371/journal.pone.0006520.g006
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by Listeria monocytogenes promotes tumor growth [3]. In the end
of this study, Kim et al have reported that TLR2 plays a critical
role in the metastasis of Lewis lung carcinoma through an
interaction between TLR2/TLR6 dimmer and extracellular
matrix proteoglycan versican [23,24]. However, it is also reported
that activation of TLR2 by endogenous HMGB1 contributes to
the anti-tumor immunity against to brain tumor [25]. These
evidences suggest the complex roles of TLR2 in regulation of
adaptive immunity [26].
Our studies not only demonstrate that targeting TLR2
generates metastases clearing immunity, but also reveals a signal
transduction pathway in the tumor by which HSP60 liberated
from B16 cells, causes a persistent activation of TLR2 to maintain
the constitutive activity and function of Stat3 in these cells and
determine the development of tumor immune tolerance. This
conclusion is derived from and supported by our and other’s
observations. Firstly, the highly metastatic B16 cells not only
release higher level of HSP60, but also have a higher-level
expression of TLR2 and basal activity of Stat3 compared to low
metastatic B16-F1 cells. Secondly, HSP60 activation of TLR2
mediates the expression and phosphorylation of Stat3 in tumor
cells. Consensually, recombinant human HSP60 activates TLR2
and Stat3 and subsequently up-regulates the expression of SOCS3
[27]. Also, the TLR2/TLR6 heterodimer is involved in phos-
phorylation or nuclear translocation of Stat3 induced by
macrophage activating lipopeptide-2 or LcrV of Yersinia pestis
[28,29]. Thirdly, TLR2 mediated the HSP60-stimulated the
expression of Stat3-controled suppressive factors, such as IL-10,
IL-13, TGF-b1 and CCL22. Indeed, HSP60 has been indicated to
induce suppressive responses and inhibit Th1 response through
TLR2 signaling [30]. Fourthly, the TLR2 activation of Stat3 is
partially dependent of IL-6 and IL-10.
The immunosuppressive microenvironment induced by grow-
ing tumors is a major obstacle to develop active immunothera-
peutic approaches for cancer due to its suppression in the
protective anti-tumor immunity. The current immunotherapy is
only able to increase tumoricidal CD8
+ T cells, but are not able to
eliminate the immunosuppressive factors, which is a main reason
for the failure of cancer immunotherapy [31,32]. Our work
indicates that targeting TLR2 not only enhances the tumoricidal
CD8
+ T cells, but also significantly eliminates the immunosup-
pressive cells and factors in tumor sites to enhance the efficacy of
anti-tumor immunity [33]. In general, M1 macrophages induced
by iNOS are tumoricidal while M2 macrophages induced by IL-
10 or IL-13 facilitate tumor growth and metastasis, inhibit the
generation of M1 macrophages, and block immune surveillance
[34]. The CD8
+ T cells, when in sufficient abundance and
directed against the appropriate tumor antigens, can monitor the
development of the tumor and possibly eradicate it [5]. Moreover,
targeting TLR2 inhibits the expression of chemokines CCL22,
MCP-1 and CCR8 to attenuate the recruitment of suppressive
immune cells to the tumor microenvironment [26,35] and result in
an overall reduction of suppressive cytokines in the tumor tissue.
In summary, TLR2 on both tumor and host cells plays a crucial
role in the establishment of a tumor-induced immunosuppressive
environment, and targeting TLR2 leads, directly or indirectly, to
induction of strong anti-tumor immunity, which puts TLR2 in an
unique position to be a promising target for cancer immunother-
apy. Despite that cytostatic chemotherapeutics may be useful in
destroying tumor cells and debulking the tumor, they can also
change anti-tumor effector cells and thereby cause long-lasting
damage to the immunological self defense of the patients [36].
Thus, combining immunotherapy with chemotherapy is a
reasonable therapeutic synergy with general applicability to many
cancers. Indeed, we find that combining the cytostatic agent GC
with the anti-TLR2 Ab increases the efficacy against tumor
metastasis when compared to GC treatment alone. The anti-
TLR2 Ab or TLR2 antagonist, especially combined with a
chemotherapeutic agent, has great potential to prevent and treat
tumor metastases.
Materials and Methods
Reagents
Ultra pure Ec-LPS and Pam3Cys were obtained from
InvivoGen (San Diego, CA). LPS (011:B4) were from Sigma-
Aldrich (Shanghai, China). FITC-, PE-, APC- or PE-Cy5-
conjugated anti-mouse CD11c, MHC I, MHC II, CD3, CD4,
CD8, CD11b, CD40, CD80, CD86, CD206, F4/80, FoxP3,
TLR2 (clone mT2.7), TLR4 (clone UT41), CD25 Abs and Stat3
inhibitory peptide (Stat3I) were from eBioscience (San Diego, CA).
TLR2-neutralizing mAb (clone mT2.4) was from Abcam (Cam-
bridge, UK) and anti-TLR4 mAb (clone MTS510) from
BioLegend (San Diego, CA). The blocking effects of TLR2- and
TLR4- neutralizing mAb were proved as described previously
[14,17,18]. Anti-b-actin and Stat3 Abs were from Santa Cruz
Biotechnology Inc (Santa Cruz, CA). Anti-phosphorylated Stat3
(pStat3) Ab was from Cell-Signaling Technology Inc (Danvers,
MA). ECL plus western blotting detection reagents were from
Amersham Biosciences (Piscataway, NJ). Purified recombinant
murine (rm) IL-6 and mIL-10 were from PeproTech (Rocky Hill,
NJ). Fibronectin peptide was from Sigma-Aldrich. The ELISA kit
for HSP60 was purchased from Stressgen Biotech Corp (San
Diego, CA). ELISA kits for IFN-c, TGF-b1, IL-10 and MCP-1
were from e-Bioscience (San Diego, CA). Endotoxin in solution of
TLR2- or TLR4- neutralizing Ab was lower than 0.01 ng/mL
tested by a Limulus amebocyte lysate assay (BioWhittaker,
Walkersville, MD).
Animals, tumor cells, and in vivo metastasis model of B16
melanoma cells
Female C57BL/6J mice (16 g61 g, 5-week old) were from the
Vital River Lab Animal Technology Co. Ltd (Beijing, China).
TLR2
2/2, TLR4
2/2 and corresponding WT mice were
purchased from Jackson laboratory (Bar Harbor, Maine, USA).
Murine melanoma cells B16-F10 (B16 cells, CRL-647) and B16-
F1 (CRL-6323) were purchased from ATCC (Rockville, MD,
USA) and maintained in DMEM supplemented with 10% FBS for
mouse injection as described previously [37]. TLR2pre and
TLR4pre groups were treated i.v. with anti-TLR2 or TLR4 Ab
(200 mg/kg) on day 0 and 7 and TLR2aft and TLR4aft groups
were treated i.v. with anti-TLR2 or TLR4 Ab on day 3 and 10
after the injection of tumor cells. TLR2KD-B16 and TLR4KD-
B16 groups were injected with the TLR2 KD- or TLR4 KD- B16
cells. To investigate the effects of the combination of anti-TLR2
Ab and gemcitabine (GC) on the survival of B16-bearing mice, the
mice were injected i.p. with GC (50 mg/kg/3d) for three times
beginning from day 3 after the tumor cells’ injection, and then,
with anti-TLR2 Ab (200 mg/kg) for three times beginning from
day 10 after the tumor cells’ injection. In the end of experiments,
the mice were sacrificed by excessive anesthesia. The pulmonary
metastasis nodes were calibrated, and the lung index was
determined by lung weight (mg) per body weight (g). The left
lung lobes were perfused with 10% neutral-buffered formalin
containing a phosphatase inhibitor cocktail (200 mM sodium
fluoride and 200 mM sodium pervanadate), placed in a fixative for
approximately 24 hours, stained for H&E, and evaluated by light
TLR2 and Tumor Metastasis
PLoS ONE | www.plosone.org 9 August 2009 | Volume 4 | Issue 8 | e6520microscopy. The right lung lobes were snap-frozen and stored at
280uC until further analysis. The care and treatment of
experimental animals was in accordance with institutional
guidelines at the Experimental Animal Center of Chinese
Academy of Medical Sciences.
Single cell suspensions of lung
Single cell suspension was obtained from murine lungs as
described previously with minor modifications [38]. Briefly, lungs
were minced to ,1 mm pieces and resuspended in 2 mL of
dispase containing collagenase (2 mg/mL) and DNase (50 mg/mL).
Digested lungs were resuspended in DMEM containing 10% FBS
and sequentially filtered through 100 mm filters.
Invasion assay
The migratory ability of tumor cells was assayed in Transwells
(Costar, Cambridge, MA) as reported previously [39]. The
polycarbonate filters were coated with fibronectin (0.5 mgi n
50 mL) before invasion assays. The tumor cells were seeded in a
suitable concentration in the upper compartment for 12 h. The
filters were harvested, fixed with 4% paraformaldehyde for
10 min, and stained with 0.5% Toluidine blue. The cells on the
upper surface of the filters were removed by wiping with cotton
swabs. The cells on the lower surface were imaged and counted in
six predetermined fields at a magnification of 206.
Growth assay
B16 cells were treated with Ec-LPS, Pam3Cys, TLR2- or
TLR4- shRNA, or bleomycin with indicated concentration in the
legend of Figure 1 for 48 h. The proliferation assay was performed
with a proliferation kit (Roche Diagnostics) following the
manufacturer’s instructions. Before the addition of MTT, the
cells were washed with warm culture media by spinning the plate
at 500 rpm for 3 min and then discarding the supernatant.
Flow cytometry analysis
The expressions of surface or intracellular molecules were
analyzed using multicolor flow cytometry as described previously
[40] and modified by this laboratory [14]. Expression and
phosphorylation of Stat3 were analyzed by intracellular flow
cytometry. Briefly, exponential growth B16-F10 cells were
stimulated indicated in the legend of Figure 2. Cells were stained
with pStat3 FITC or Stat3 TRITC Ab and expression or
phosphorylation of Stat3 was analyzed by intracellular flow
cytometry. The fluorescence data was collected and analyzed as
indicated.
ELISA
HSP60 in the supernatant of tumor cells or in the BALF was
determined by ELISA following the manufacturer’s instructions.
The limit of ELISA for HSP60 is 1 pg/mL. The level of cytokines
in homogenates was determined by ELISA following the
manufacturer’s instructions. The limit of each ELISA for cytokines
was 5 pg/mL. The lung homogenates were prepared as described
previously [41].
RT-PCR
Total RNAs were extracted from cultured cells or lung
homogenates using TRIzol Reagent (Life Technologies, Gaithers-
burg, MD). cDNAs were synthesized from 1.0 mg of total RNA
using the Moloney murine leukemia virus reverse transcriptase
(Invitrogen, NJ). The mRNA expression was detected by RT-PCR
using the primers in Table S1. The PCR products were visualized
on ethidium bromide-stained 1.4% agarose gels. The intensity of
band was analyzed by the Gel-proH Analyzer (Gel-Pro Plus
Version 6.0).
Confocal microscopy
B16 cells were fixed, permeabilized and washed. To avoid
nonspecific binding, the cells were incubated in PBS containing
2% BSA for 30 min at room temperature before being stained
with the corresponding primary Ab overnight at 4uC. Cells were
washed twice and incubated with fluorochrome labeled secondary
antibodies (1:200) for 30 min followed by three washes. Images
were obtained with Leica SP2 confocal microscope (Leica
Microsystems, PA) and analyzed with Leica confocal software.
Morphological evaluation of lung sections
The excised lungs were fixed with 4% paraformaldehyde and
embedded in paraffin for histopathological examination. Five mm
thick tissue sections were prepared and stained with H&E. The
nuclear division stages were assessed by two professional
researchers of pathology, who were blinded to the groups. The
signal intensity were determined by Image-Pro Plus image analysis
software following a previous method [42]. The integrated optical
density (IOD) represented averages from 10 non-overlapping
images of each lung specimen. All quantitative studies were
performed blinded with regards to animal genotype.
RNA inference
The pSilencer 1.0 U6 vector, expressing small hairpin RNA
(shRNA) against TLR2, TLR6 or Dectin-1, was constructed. The
vector contains a DNA template for the synthesis of siRNA under
the control of the U6 promoter. Cells were grown in Petri dishes
and arrested in medium containing 0.4% serum 6 hours before
transfection with 0.2 mmol/L shRNA targeting TLR2, TLR6 or
Dectin-1. The targeted sequences for the RNAi of mouse TLR2,
TLR6, Dectin-1, and control were GGAACAGAGTGGCAA-
CAGT, AGGAACCTTACTCATGTCC, GACAGCTTCCT
ATCAAGAA, and GCGAGTAGCGCTAGGAAGT, respective-
ly. The targeted sequence for the RNAi of human TLR2 was
CCTCAGGGCTCACAGAAGCTGT AAA. The constructs were
inserted into the pSilencer
TM Hydro using BamH1 and Xba1
restriction sides. A pSilencer-negative vector served as a non-
silencing control. Cells were transfected in a 10 cm plate by the
lipotransfection method (Lipofectamine 2000, Invitrogen) accord-
ing to the manufacturer’s recommendation.
Western blot
The B16 cells were treated with or without indicated agents for
24 h. The membrane proteins were extracted from B16 cells using
a Qproteome plasma membrane protein kit (Qiagen Inc., CA).
Protein concentrations were determined with Coomassie Plus
reagent. SDS PAGE and Western blot were conducted as
described previously [14].
Transfection
The Stat3C vector and its control vector were endowed from Dr
Yan (Department of Medicine and Cell Biology & Physiology,
Washington University School of Medicine, St. Louis, MO). The
B16 cells were transfected with either Stat3C vector or control
vector using the Lipofectamine method as described [43]. At 24 h
post transfection, cells were transferred into a medium containing
10% FCS and supplemented with 2 mg/ml puromycin and
100 ng/ml doxycycline. Nontransfected cells were killed by
puromycin and 6 days later survivor colonies were picked up
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were maintained on puromycin and doxycycline medium, unless
otherwise indicated.
Statistics
Data are expressed as mean6standard error (SE). Groups were
compared by using one-way ANOVA followed by a Tukey-
Kramer’s or Dunnett’s multiple comparisons test. Comparisons
between two groups were performed by unpaired Students’s t tests.
The survival rates were analyzed by the Kaplan-Meier method. A
P value,0.05 was considered significant.
Supporting Information
Methods S1 Supplemental material and methods
Found at: doi:10.1371/journal.pone.0006520.s001 (0.06 MB
DOC)
Figure S1 TLR2 expressed on tumor cells. (A-B) The expression
of TLR2 and TLR4 on B16 cells was detected by immunofluo-
rescence microscopy (A) or by immunoblot (B). (C) The expression
profile of TLR1-9 mRNAs in B16 cells was detected by RT-PCR.
(D) Knockdown of TLR2 did not change the growth of B16 cells
(E) TLR2 expressed on several human tumor cell lines, including
human melanoma cell (A375), lung cancer cell (A549), colon
cancer cell (HCT8), hepatic tumor cell (H7402), and breast tumor
cell (MCF7 and MDA-MD231).
Found at: doi:10.1371/journal.pone.0006520.s002 (3.28 MB TIF)
Figure S2 Pam3Cys enhanced the release of cytokines, chemo-
kines and the expression of chemokine receptors by B16
melanomas in vitro. B16 cells were pretreated with TLR2- or
TLR4- shRNA for 16 hs before the addition of ultra-purified
Pam3Cys (1 A ˆmg/mL). After incubation for 24 h, the expressions
of IL-6 (A), IL-10 (B), IL-13 (C), TGF-I ˆ21 (D) and MCP-1 (E) were
determined with intracellular staining assays. The expressions of
CCL22 (F) and CCR8 (G) were determined by quantitative real-
time PCR. Data are represented as the mean A ˆ6SE of four
independent experiments. *P,0.05, ** P,0.01, *** P,0.001
versus untreated group; #P,0.05, ##P,0.01, ###P,0.001
versus Pam3Cys treated group.
Found at: doi:10.1371/journal.pone.0006520.s003 (0.72 MB TIF)
Figure S3 TLR2 mediated the HSP60 induced expressions of
suppressive cytokines, chemokines and chemokine receptors. B16
cells were pretreated with a TLR2 shRNA 16 hs before the
addition of HSP60 (20 ng/mL). After incubation for 24 h, the
levels of IL-6 (A), IL-10 (B), IL-13 (C), TGF-b1 (D) and MCP-1 (E)
were determined with intracellular flow cytometry. The expres-
sions of CCL22 (F) and CCR8 (G) were determined by
quantitative real-time PCR. Data are represented as mean6SE
of four experiments. *P,0.05, **P,0.01, ***P,0.001, versus
control; #P,0.05, ##P,0.01, ###P,0.001, versus HSP60
treated cells.
Found at: doi:10.1371/journal.pone.0006520.s004 (0.59 MB TIF)
Figure S4 Activation of Stat3 mediated Pam3Cys stimulation of
gene expression involved in tumor progression and metastasis. B16
cells were pretreated with a Stat3I (10 A ˆmg/mL) for one hour
before the addition of Pam3Cys (1 A ˆmg/mL). Otherwise, B16 cells
with or without Stat3C (S3C) vector were treated with TLR2
shRNA for 16 h after transfection. After incubation for 24 h, the
expressions of survivin (A), VEGF (B), HIF-I ˆ6(C), p53 (D), c-myc
(E), IL-10 (F), IL-13 (G) and HSP60 (H) were determined with
intracellular staining assays. Data are represented as mean A ˆ6SE
of three experiments. *P,0.05, ** P,0.01, *** P,0.001 versus
untreated cells; # P,0.05, ## P,0.01, ### P,0.001 versus
TLR2 shRNA treated cells; $P,0.05, $$P,0.01, $$$P,0.001
versus Pam3Cys treated cells.
Found at: doi:10.1371/journal.pone.0006520.s005 (0.79 MB TIF)
Figure S5 HSP60 released by B16 cells maintained the
constitutive activity of Stat3 through activation of TLR2. (A)
High metastatic B16-F10 cells produced much more HSP60 than
low metastatic B16-F1 cells. The B16-F10 cells and B16-F1 cells
were cultured in a medium containing different concentrations of
serum. After incubation for 24 h, the supernatants were collected
and the level of HSP60 was detected by ELISA. (B–D) Targeting
TLR2 antagonized HSP60 stimulated expression of metastasis
associated genes in B16 cells. After treatment with HSP60
(100 ng/mL) or HSP60 plus TLR2 shRNA for 24 h, the
expression of VEGF (B) and IL-10 (C) and the phosphorylation
of Stat3 (D) were determined with intracellular flow cytometry.
Data are represented as mean A ˆ6SE of four independent
experiments. *P,0.05, ** P,0.01, ***P,0.001 versus untreated
group; #P,0.05, ##P,0.01, ###P,0.001 versus HSP60
treated group.
Found at: doi:10.1371/journal.pone.0006520.s006 (0.48 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0006520.s007 (0.07 MB
DOC)
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